Ocrelizumab Discontinuation in Relapsing Multiple Sclerosis

NCT05285891 · clinicaltrials.gov ↗

PHASE4

Phase

RECRUITING

Status

123

Enrollment

NIH

Sponsor class

Conditions

Multiple Sclerosis

Interventions

DRUG: Ocrelizumab
DRUG: Placebo for Ocrelizumab

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)

Collaborators

[object Object]
[object Object]
[object Object]